Primary therapy of Waldenström macroglobulinemia (WM) with weekly bortezomib, low-dose dexamethasone, and rituximab (BDR): Long-term results of a phase 2 study of the European Myeloma Network (EMN)

  1. Dimopoulos, M.A.
  2. Garćia-Sanz, R.
  3. Gavriatopoulou, M.
  4. Morel, P.
  5. Kyrtsonis, M.-C.
  6. Michalis, E.
  7. Kartasis, Z.
  8. Leleu, X.
  9. Palladini, G.
  10. Tedeschi, A.
  11. Gika, D.
  12. Merlini, G.
  13. Kastritis, E.
  14. Sonneveld, P.
Revue:
Blood

ISSN: 0006-4971,  1528-0020

Année de publication: 2013

Volumen: 122

Número: 19

Pages: 3276-3282

Type: Article

DOI: 10.1182/BLOOD-2013-05-503862 GOOGLE SCHOLAR lock_openAccès ouvert editor